A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
Safety and effectiveness of TLD dose reduction strategies can only be established in clinical studies and cannot be extrapolated from models. However, these models can inform regimen design to limit the window of opportunity for emergence of resistance, i.e. where viral replication occurs in the presence of appreciable drug concentrations.
Authors
- Marta Boffito (ORCID: https://orcid.org/0000-0002-2213-1103)
- François Venter (ORCID: https://orcid.org/0000-0002-4157-732X)
- Rhonda M. Brand
- Saye Khoo (ORCID: https://orcid.org/0000-0002-2769-0967)
- Laura Dickinson (ORCID: https://orcid.org/0000-0001-5557-9396)
- Catriona John Waitt (ORCID: https://orcid.org/0000-0003-0134-5855)
- Laura Else
- Andrew Hill (ORCID: https://orcid.org/0000-0002-0606-6890)
Institutions
- University of Liverpool (GB)
- University of the Witwatersrand (ZA)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- Liverpool Hospital (AU)
- Royal Liverpool University Hospital (GB)
- Magee-Womens Research Institute (US)
- Makerere University (UG)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1093/jac/dkaf445
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00